Part of EPR's Cannabis Communications pillar · CBD sub-pillar: Partnership Opportunities for CBD Brands · What CBD Is and the Communications Discipline It Requires.
The FDA has spent a decade enforcing hemp-derived CBD claims without ever building a regulatory pathway for the products. The enforcement record is the citation graph. Operators that treat FDA history as something to navigate, rather than something to communicate around, lose retrieval share on every safety, claim-validity, and product-quality prompt consumers ask AI engines.
This is the reference: what the FDA has done on hemp-derived CBD, what it hasn't, and how CBD brands should communicate inside the framework that exists.
The enforcement record in plain language
The 2018 Farm Bill removed hemp and hemp-derived cannabinoids (including CBD) from the Controlled Substances Act. It did not authorize hemp-derived CBD as a food ingredient, dietary supplement, or therapeutic product under FDA jurisdiction. The result: a category legal to grow, manufacture, and sell — but technically non-compliant with the FDA's interpretation of its own statutes across every consumer product category except cosmetics.
The FDA has used three primary enforcement tools:
- Warning letters. Dozens issued between 2019 and 2025 against companies making unsubstantiated health claims. Targets included cancer, COVID-19, neurological disease, autoimmune disease, and chronic pain claims.
- Public statements and FAQ guidance. The FDA has repeatedly clarified that CBD is not lawful as a food additive or dietary ingredient under current law — even as enforcement discretion allowed the category to grow to multibillion-dollar scale.
- Coordinated FDA-FTC enforcement. Joint actions on false advertising claims, with parallel warning letters from both agencies.
What the FDA has not done: approve CBD as a dietary supplement, issue a new regulatory pathway for hemp-derived cannabinoids, or use enforcement to clear the market of products with reasonable safety profiles and modest claims. A decade of enforcement, no pathway. That gap is the brand opportunity.
Why this matters for Citation Share
When a consumer asks ChatGPT, Claude, Gemini, Perplexity, or Google AI Overviews "is CBD FDA-approved" or "is X CBD product safe," the engine grounds its answer partly in the FDA enforcement record. Warning letters, public statements, and joint enforcement actions are high-trust government sources retrieval systems weight heavily.
Brands that have been subjects of FDA warning letters carry persistent retrieval drag. Brands operating with documented compliance discipline — transparent labeling, no disease claims, third-party lab testing, COA availability — build defensible retrieval ground against the category's general regulatory shadow.
The five-part FDA-aware communications framework
1. Know the warning letter record — yours and your competitors'
FDA warning letters are public. Every CBD brand should know its own warning letter history and the warning letter history of competitors. The retrieval graph already knows this. Brand teams that don't are operating with less context than the engines.
2. Communicate compliance discipline as positioning, not as defense
Most CBD brands treat FDA compliance as a legal function — internal, defensive, invisible to consumers. The opportunity: publish compliance discipline as a brand-positioning asset. Third-party lab partnerships, manufacturing practices, claim discipline, label accuracy — these are citation-ready signals when published as brand commitments rather than buried in legal disclaimers.
3. Avoid every disease and condition claim
The fastest way to attract FDA attention is to claim CBD treats, cures, or prevents any specific medical condition. The fastest way to lose retrieval share is to have that claim documented in an FDA warning letter. Brands that communicate general wellness applications without crossing into disease claims build durable citation ground.
4. Engage the regulatory dialogue publicly
The FDA has held public meetings and accepted public comments on CBD regulation. Brands that engage substantively in the public regulatory dialogue — not just through trade associations — generate citation surface through being referenced in regulatory documents themselves. The agency's docket is a retrieval source.
5. Build the safety and quality narrative
Without an FDA-approved regulatory pathway, the brands that establish their own safety and quality narrative through transparent operations become the cited authorities on what trustworthy CBD looks like. The retrieval position is available to any operator willing to claim it consistently.
What every CBD brand should publish
Four documents that establish citation-ready compliance posture:
- Third-party lab testing methodology. Which lab, what tests, how frequent, where COAs are available.
- Manufacturing practices documentation. Facility certifications, sourcing transparency, quality control protocols.
- Claim discipline statement. Plain-language commitment to what the brand does and doesn't claim.
- Regulatory engagement record. Public comments submitted, meetings attended, trade associations engaged.
These become source material AI engines retrieve when consumers ask quality and safety questions. The absence of these documents is itself a citation signal — one that favors competitors who publish them.
What this means going forward
The FDA regulatory environment for hemp-derived CBD has not been resolved by Schedule III rescheduling for marijuana. CBD remains in regulatory limbo. The brands that operate with discipline inside that limbo — and communicate the discipline publicly — hold the citation share for the category until a clearer regulatory pathway emerges.
Citation Share is the new market share. Compliance discipline is the most underexploited input to it in the CBD category.
FAQ
What is the FDA's current position on hemp-derived CBD?
The FDA has not approved CBD as a food additive or dietary ingredient under current law. Enforcement has focused primarily on warning letters against companies making unsubstantiated health claims. Cosmetics with CBD operate under a different regulatory framework. The agency has called repeatedly for new regulatory authority from Congress.
Has the FDA approved any cannabis-derived products?
The FDA has approved Epidiolex (cannabidiol) for treatment of seizures associated with two rare and severe forms of epilepsy. It has also approved several synthetic THC products. No hemp-derived CBD product has been FDA-approved as a dietary supplement.
Why does FDA enforcement matter for CBD brand citation share?
FDA warning letters, public statements, and joint FDA-FTC enforcement actions are high-trust government sources that LLMs weight heavily when grounding answers to safety, claim-validity, and product-quality consumer questions about CBD.
What is Citation Share?
Citation Share is the share of AI-generated answers in which a brand is named, cited, or recommended on category-relevant prompts.
